SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global nanopharmaceuticals market was valued at US$ 28,434.3 million in 2017, and is projected to exhibit a CAGR of 22.1% over the forecast period (2018 – 2026).
Key Trends and Analysis of the Nanopharmaceuticals Market:
Various advantages of nanopharmaceuticals over other medicines such as faster drug delivery and higher efficiency, increase in research and development activities for discovery of new products for precision medicine, cardiovascular, and other diseases, technological advancements in regenerative medicine, and high prevalence of neurological disorders and cancer are some of the factors that will increase growth of the nanopharmaceuticals market.
Ask for a Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/2485
Market players are focused on R&D activities for novel materials for treatment of cancer and other diseases. Moreover, key players in the nanopharmaceuticals market are committed to offering new and improved products in order to address critical unmet needs of patients. For example, in August 2017, Jazz Pharmaceuticals received FDA approval for Vyxeos, used for the treatment of acute myeloid leukemia.
Furthermore, key players operating in the market are focused on adopting various business strategies such as acquisition strategies in order to gain access to innovative products and expand its product offerings in the potential market. For instance, in March 2018, Celgene Corporation acquired Juno Therapeutics, Inc., developer of chimeric antigen receptor. This acquisition will support Celgene to expand its product offering and increase its operational capabilities.
However, need for improved characterization, lack of regulatory guidelines, and toxicity issues are expected to hinder the market growth. As per the P&T Community Journal, Volume 42, December 2017, Food and Drug Administration (FDA) issued four guidance documents for industry regarding the use of nanotechnology in FDA-regulated products, which include nano drugs in June 2014.
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/nanopharmaceuticals-market-2485
Key Market Takeaways:
- The nanopharmaceuticals market is expected to exhibit a CAGR of 22.1% during the forecast period (2018 – 2026). This growth is attributed to increasing incidences of cardiovascular diseases, cancer, and infectious diseases, and advantages of nanopharmaceuticals over macroscopic level of medicines. According to the World Health Organization (WHO) Factsheet November 2016, estimated around 16% of all deaths of children below 5 years in 2015 were due to Pneumonia.
- Market growth is attributed to rising approvals and launches of novel products for treatment in neurological disorders. For instance, in August 2009, Janssen Pharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for Invega Sustenna used in treatment of schizophrenia in adults.
- Key players in the market are focused on adopting mergers and acquisitions strategies to enhance its product portfolio, which in turn is expected to propel the market growth over the forecast period. For instance, in 2017, Gilead Sciences acquired Kite Pharma.
- Key players operating in the global nanopharmaceuticals market include, Abbott, GlaxoSmithKline plc., Eli Lilly and Company, Astrazeneca plc., Novavax, Inc., Stryker Corporation, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Tanabe Pharma Corporation, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma Inc., Navidea Biopharmaceuticals, Inc., AbbVie Inc., AMAG Pharmaceuticals, Amgen Inc., Astellas Pharma Inc., Celgene Corporation, Gilead Sciences, Inc., JOHNSON & JOHNSON, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Hoffmann-La Roche AG, Sanofi S.A, Shire Plc., and Teva Pharmaceuticals Industries Limited
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
